Dr. Carey on Treating Triple-Negative Breast Cancer

Video

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Carey says the main challenge in treating triple-negative breast cancer is that physicians are limited to chemotherapy outside of clinical trials. However, there are relatively low-toxicity chemotherapy regimens that are used in the treatment of these patients.

Triple-negative breast cancer tends to behave like other subsets where taxanes are effective, and it has been shown that platinum drugs are as effective as taxanes in the first-line setting, Carey says.

Even though treatment in the space is limited to chemotherapy, Carey says there are 4-5 agents that can be used for the treatment of triple-negative breast cancer.

<<<

View more from the 32nd Annual Miami Breast Cancer Conference

Related Videos
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD